Skip to content

A Study on the Regulation of M2d Macrophage Differentiation in the Immune Microenvironment by EZH2/TIMP2 Epigenetic Silencing: Clinical Efficacy and Molecular Mechanism of Luo in Treating Endometriosis (EMs)

A Study on the Regulation of M2d Macrophage Differentiation in the Immune Microenvironment by EZH2/TIMP2 Epigenetic Silencing: Clinical Efficacy and Molecular Mechanism of Luo in Treating Endometriosis (EMs)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001549
Enrollment
Unknown
Registered
2026-06-20
Start date
2025-06-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

GnRH-a + Luo Endometriosis Formula Granules Group:In addition to the treatment with Goserelin sustained-release implant, Luo's Nei Yi Fang granules, a Chinese herbal medicine, were additionally admini
Non-exposure group (Western medicine treatment group):Only Goserelin sustained-release implant therapy.

Sponsors

Zhongshan City Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for laparoscopic and pathological examination of ovarian-type endometriosis (EMs); (2) First laparoscopic conservative surgery, with surgical staging classified as ASRM stage III to IV; (3) Meets the diagnostic criteria for the traditional Chinese medicine (TCM) syndrome of qi stagnation and blood stasis; (4) Aged between 18 and 40 years, with regular menstrual cycles; (5) Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant, breastfeeding, or planning pregnancy within the next 6 months; (2) Individuals with known allergies to the components of this medication or adverse reactions to it; (3) Patients with concurrent adenomyosis, uterine fibroids (diameter >4cm), pelvic inflammatory masses, or pelvic malignant tumors; (4) Individuals who have taken Western medicine or Chinese medicine with similar functions for the treatment of endometriosis within the past 3 months, such as dydrogesterone, drospirenone, gestrinone, Shaofu Zhuyu granules, or Guizhi Fuling capsules; (5) Patients with concurrent cardiovascular, hepatic, renal, endocrine, hematological system diseases, malignant tumors, or neurological or psychiatric disorders; (6) Individuals who refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Anti-Müllerian Hormone (AMH);Six Sex Hormones;Carbohydrate Antigen 125;Inflammatory factors in peripheral venous blood;

Secondary

MeasureTime frame
Visual Analog Scale;Endometriosis Patient Quality of Life Scale;TCM syndrome score;Recurrence rate;

Countries

China

Contacts

Public ContactZhong Weilan

Zhongshan City Traditional Chinese Medicine Hospital

Zhongweilan1971@163.com18638008615

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026